Integral Diagnostics Ltd
IDX: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|S!>J^N> | LOCK|Ykz | LOCK|yZl&?Fz |
Integral Earnings: Lagging Industry Growth but Margin Recovery Underway
No-moat Integral’s first-half fiscal 2024 Australian revenue increased 7.8% on the previous corresponding period, driven by increases to government funding and out-of-pocket fees, but was below market growth of 9.5%. We trim our group revenue forecasts by 3% on average over the next 10 years, but this is largely offset by the time value of money and lower forecast expenditure. Our midcycle EBITDA margin forecast increases by 50 basis points to 25.8%, and we maintain our AUD 3.60 fair value estimate with shares remaining undervalued.
